{
    "clinical_study": {
        "@rank": "156427", 
        "acronym": "AReMIS", 
        "arm_group": [
            {
                "arm_group_label": "Control group", 
                "description": "Patients aged 18 years or more with an acute coronary syndrome, agreed to participate and able to answer an interview in French and/or providing the details of an alternative replier (proxy) if necessary"
            }, 
            {
                "arm_group_label": "Case group", 
                "description": "Patients aged 18 years or more with a history of acute coronary syndrome (i.e. a recurrent MI after myocardial history or unstable angina), agreed to participate and able to answer an interview in French and/or providing the details of an alternative replier (proxy) if necessary"
            }
        ], 
        "brief_summary": {
            "textblock": "Prevention of cardiovascular events by antiplatelet agents after acute coronary syndrome"
        }, 
        "brief_title": "Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Coronary Syndrome", 
        "condition_browse": {
            "mesh_term": "Acute Coronary Syndrome"
        }, 
        "detailed_description": {
            "textblock": "AReMIS (Antiplatelet and Recurrent Myocardial Infarction Study) To compare the relative risk\n      of new myocardial infarction (recurrent myocardial infarction or 'rMI') in patients with a\n      history of acute coronary syndrome ('ACS': unstable angina or myocardial infarction), using\n      ticagrelor, clopidogrel or prasugrel (if applicable) or none of these treatments, where\n      aspirin is considered a covariate."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients aged 18 years or more, both genders, with an acute coronary syndrome (ACS),\n        agreed to participate and able to respond to an interview in French and/or providing the\n        details of an alternative replier (proxy) if necessary.\n\n        No Exclusion Criteria."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients aged 18 years or more, both genders,with an acute coronary syndrome, agreed to\n        participate and able to respond to an interview in French and/or providing the details of\n        an alternative replier (proxy) if necessary."
            }
        }, 
        "enrollment": {
            "#text": "3750", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01952392", 
            "org_study_id": "NIS-CFR-BRI-2012/1"
        }, 
        "intervention_browse": {
            "mesh_term": "Platelet Aggregation Inhibitors"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Effectiveness study", 
            "Acute coronary Syndrome", 
            "Real-life", 
            "France"
        ], 
        "lastchanged_date": "May 16, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Paris", 
                    "country": "France"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_groups": "2", 
        "official_title": "Study on the Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome", 
        "overall_contact": {
            "email": "ClinicalTrialTransparency@astrazeneca.com", 
            "last_name": "Florence Thomas", 
            "phone": "+33141294025"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "'CNIL': French Data Protection Authority, France.", 
                "'HAS TC': Transparency Commission of the Haute Autorit\u00e9 de Sant\u00e9 (French National Authority for Health), France.", 
                "'CEPS': Committee for Pricing of Healthcare Products, France."
            ]
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "History of coagulation and vascular disorders History of cerebrovascular accidents Cardiovascular risk factors", 
                "measure": "Medical information", 
                "safety_issue": "No", 
                "time_frame": "At baseline visit"
            }, 
            {
                "description": "Current exposure: within 24 hours (before date of recurrent MI). Exposure to clopidogrel, ticagrelor, prasugrel, aspirin, other antiplatelet drugs.", 
                "measure": "Drug exposure", 
                "safety_issue": "No", 
                "time_frame": "Current"
            }, 
            {
                "description": "Recent exposure: in the week (7 days) preceding the recurrent MI. Exposure to clopidogrel, ticagrelor, prasugrel, aspirin, other antiplatelet drugs.", 
                "measure": "Drug exposure", 
                "safety_issue": "No", 
                "time_frame": "Recent"
            }, 
            {
                "description": "Past exposure: more than a week (7 days) before the recurrent MI and until the ACS index. Exposure to clopidogrel, ticagrelor, prasugrel, aspirin, other antiplatelet drugs.", 
                "measure": "Drug exposure", 
                "safety_issue": "No", 
                "time_frame": "Past"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01952392"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "rMI, stroke, bleeding, death", 
            "measure": "Other medical events of interest", 
            "safety_issue": "Yes", 
            "time_frame": "During follow-up (up to 12 months)"
        }, 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}